TYR and Alzheimer disease: In terms of clinical practice, although the ATN approach is the cornerstone of disease‐modifying interventions in AD, there are still some unsuitable conditions, including operational difficulty in defining ATN positivity (+) or negativity (−), such as some biomarkers still lack widespread consensus cutoff values, and also different biomarkers, different sources (e.g., cerebrospinal fluid (CSF), plasma‐based and neuroimaging) being incorporated into one category.10